184 related articles for article (PubMed ID: 34129859)
1. Future prospects for mitosis-targeted antitumor therapies.
Serrano-Del Valle A; Reina-Ortiz C; Benedi A; Anel A; Naval J; Marzo I
Biochem Pharmacol; 2021 Aug; 190():114655. PubMed ID: 34129859
[TBL] [Abstract][Full Text] [Related]
2. Aurora kinase inhibitors: a new class of drugs targeting the regulatory mitotic system.
Pérez Fidalgo JA; Roda D; Roselló S; Rodríguez-Braun E; Cervantes A
Clin Transl Oncol; 2009 Dec; 11(12):787-98. PubMed ID: 20045785
[TBL] [Abstract][Full Text] [Related]
3. Mitosis inhibitors in anticancer therapy: When blocking the exit becomes a solution.
Henriques AC; Ribeiro D; Pedrosa J; Sarmento B; Silva PMA; Bousbaa H
Cancer Lett; 2019 Jan; 440-441():64-81. PubMed ID: 30312726
[TBL] [Abstract][Full Text] [Related]
4. Antimitotic drugs in cancer chemotherapy: promises and pitfalls.
Marzo I; Naval J
Biochem Pharmacol; 2013 Sep; 86(6):703-10. PubMed ID: 23886991
[TBL] [Abstract][Full Text] [Related]
5. Target driven preclinical screening for new antimitotic chemotherapy agents.
Novío S; Freire-Garabal M; Núñez MJ
Curr Top Med Chem; 2014; 14(20):2263-71. PubMed ID: 25434356
[TBL] [Abstract][Full Text] [Related]
6. Targeting mitotic exit with hyperthermia or APC/C inhibition to increase paclitaxel efficacy.
Giovinazzi S; Bellapu D; Morozov VM; Ishov AM
Cell Cycle; 2013 Aug; 12(16):2598-607. PubMed ID: 23907120
[TBL] [Abstract][Full Text] [Related]
7. Mitosis-targeted anti-cancer therapies: where they stand.
Chan KS; Koh CG; Li HY
Cell Death Dis; 2012 Oct; 3(10):e411. PubMed ID: 23076219
[TBL] [Abstract][Full Text] [Related]
8. Targeting Mitosis in Cancer: Emerging Strategies.
Dominguez-Brauer C; Thu KL; Mason JM; Blaser H; Bray MR; Mak TW
Mol Cell; 2015 Nov; 60(4):524-36. PubMed ID: 26590712
[TBL] [Abstract][Full Text] [Related]
9. Clinical Development of Anti-mitotic Drugs in Cancer.
Olziersky AM; Labidi-Galy SI
Adv Exp Med Biol; 2017; 1002():125-152. PubMed ID: 28600785
[TBL] [Abstract][Full Text] [Related]
10. Co-inhibition of polo-like kinase 1 and Aurora kinases promotes mitotic catastrophe.
Li J; Hong MJ; Chow JP; Man WY; Mak JP; Ma HT; Poon RY
Oncotarget; 2015 Apr; 6(11):9327-40. PubMed ID: 25871386
[TBL] [Abstract][Full Text] [Related]
11. Natural products as new antimitotic compounds for anticancer drug development.
Paier CRK; Maranhão SS; Carneiro TR; Lima LM; Rocha DD; Santos RDS; Farias KM; Moraes-Filho MO; Pessoa C
Clinics (Sao Paulo); 2018 Dec; 73(suppl 1):e813s. PubMed ID: 30540125
[TBL] [Abstract][Full Text] [Related]
12. Mitosis as an anti-cancer drug target.
Salmela AL; Kallio MJ
Chromosoma; 2013 Oct; 122(5):431-49. PubMed ID: 23775312
[TBL] [Abstract][Full Text] [Related]
13. Anti-mitotic agents: Are they emerging molecules for cancer treatment?
Penna LS; Henriques JAP; Bonatto D
Pharmacol Ther; 2017 May; 173():67-82. PubMed ID: 28174095
[TBL] [Abstract][Full Text] [Related]
14. A Novel Eg5 Inhibitor (LY2523355) Causes Mitotic Arrest and Apoptosis in Cancer Cells and Shows Potent Antitumor Activity in Xenograft Tumor Models.
Ye XS; Fan L; Van Horn RD; Nakai R; Ohta Y; Akinaga S; Murakata C; Yamashita Y; Yin T; Credille KM; Donoho GP; Merzoug FF; Li H; Aggarwal A; Blanchard K; Westin EH
Mol Cancer Ther; 2015 Nov; 14(11):2463-72. PubMed ID: 26304237
[TBL] [Abstract][Full Text] [Related]
15. Novel Mps1 Kinase Inhibitors with Potent Antitumor Activity.
Wengner AM; Siemeister G; Koppitz M; Schulze V; Kosemund D; Klar U; Stoeckigt D; Neuhaus R; Lienau P; Bader B; Prechtl S; Raschke M; Frisk AL; von Ahsen O; Michels M; Kreft B; von Nussbaum F; Brands M; Mumberg D; Ziegelbauer K
Mol Cancer Ther; 2016 Apr; 15(4):583-92. PubMed ID: 26832791
[TBL] [Abstract][Full Text] [Related]
16. Mitosis-targeting natural products for cancer prevention and therapy.
Rao CV; Kurkjian CD; Yamada HY
Curr Drug Targets; 2012 Dec; 13(14):1820-30. PubMed ID: 23140292
[TBL] [Abstract][Full Text] [Related]
17. Mitosis and apoptosis: how is the balance set?
Topham CH; Taylor SS
Curr Opin Cell Biol; 2013 Dec; 25(6):780-5. PubMed ID: 23890995
[TBL] [Abstract][Full Text] [Related]
18. Tubulin-associated drug targets: Aurora kinases, Polo-like kinases, and others.
Warner SL; Gray PJ; Von Hoff DD
Semin Oncol; 2006 Aug; 33(4):436-48. PubMed ID: 16890798
[TBL] [Abstract][Full Text] [Related]
19. Salt-inducible kinase 3 is a novel mitotic regulator and a target for enhancing antimitotic therapeutic-mediated cell death.
Chen H; Huang S; Han X; Zhang J; Shan C; Tsang YH; Ma HT; Poon RY
Cell Death Dis; 2014 Apr; 5(4):e1177. PubMed ID: 24743732
[TBL] [Abstract][Full Text] [Related]
20. Blocking Mitotic Exit of Ovarian Cancer Cells by Pharmaceutical Inhibition of the Anaphase-Promoting Complex Reduces Chromosomal Instability.
Raab M; Sanhaji M; Zhou S; Rödel F; El-Balat A; Becker S; Strebhardt K
Neoplasia; 2019 Apr; 21(4):363-375. PubMed ID: 30851646
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
